MediciNova, Inc. (MNOV) - Financial and Strategic SWOT Analysis Review

Document Sample
MediciNova, Inc. (MNOV) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					              MediciNova, Inc. (MNOV) - Financial and Strategic SWOT Analysis
                                           Review
        Reference Code: GDPH61527FSA                                                                                          Publication Date: SEP 2012

          4350 La Jolla Village Drive, Suite 950             Phone              +1 858 3731500                  Revenue          NA
          San Diego, CA                                      Fax                +1 858 3737000                  Net Profit       -17.73 (million USD)
          92122                                              Website            www.medicinova.com              Employees        14
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           MNOV [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       MediciNova, Inc. (MediciNova) is a bio pharmaceutical company with focus on the acquiring and developing and commercializing
       novel, small-molecule therapeutics for the treatment of diseases with unmet medical need in the US. MediciNova built a portfolio
       of product candidates by acquiring product rights through license agreements with mid-sized Japanese pharmaceutical
       companies.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      MediciNova, Inc., SWOT Analysis
         Yuichi Iwaki, M.D., Ph.D.           Chief Executive Officer                  Strengths                              Weaknesses
         Jeff Himawan                        Chairman
                                                                                      Partnership and Collaborations History of Operating Losses
         Arlene M. Morris                    Director
                                                                                      Focused Research and                   Lack of In-House Manufacturing
         Hiroaki Shigeta                     Director
                                                                                      Development                            Facilities
         Tatsuo Izumi                        Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Strong Product Pipeline                Highly Competitive
         MediciNova, Inc.                                                                                                    Environment
                                                                                      Emerging Markets
        Share Price (USD) as on 10-Sep-                                  1.90                                                Uncertain R&D Outcomes
        2012
        EPS (USD)                                                       -1.20
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million USD)                                           31        GlobalData

        Enterprise Value (million USD)                                     23
        Shares Outstanding (million)                                       16
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Aug 09, 2012         MediciNova Reports Revenue Of $0.5m In Q2
                                                                                                           2012
                                                                                      May 10, 2012         MediciNova Reports Q1 2012 Results
                                                                                      Mar 29, 2012         MediciNova Reports 2011 Results
                                                                                      Nov 30, 2011         MediciNova Appoints Kousuke Nakata To
                                                                                                           Board
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData



       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




MediciNova, Inc. (MNOV) - Financial and Strategic SWOT Analysis                                                                Reference Code: GDPH61527FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       MediciNova, Inc. - Key Facts .............................................................................................................................................................. 5
       MediciNova, Inc. - Key Employees ..................................................................................................................................................... 6
       MediciNova, Inc. - Key Employee Biographies ................................................................................................................................... 7
       MediciNova, Inc. - Major Products and Services ................................................................................................................................ 8
       MediciNova, Inc. - Pharmaceutical Pipeline Products Data ................................................................................................................ 9
          MediciNova, Inc., Pipeline Products by Therapy Area .................................................................................................................... 9
          MediciNova, Inc., Pipeline Products by Development Phase........................................................................................................ 10
       MediciNova, Inc. - History................................................................................................................................................................. 12
       MediciNova, Inc. - Company Statement ........................................................................................................................................... 14
       MediciNova, Inc. - Locations And Subsidiaries................................................................................................................................. 16
          Head Office ................................................................................................................................................................................... 16
          Other Locations & Subsidiaries ..................................................................................................................................................... 16
       Section 2 – Company Analysis ......................................................................................................................................................... 17
       MediciNova, Inc. - Business Description .......................................................................................................................................... 17
       MediciNova, Inc. - SWOT Analysis ................................................................................................................................................... 18
          SWOT Analysis - Overview........................................................................................................................................................... 18
          MediciNova, Inc. - Strengths ......................................................................................................................................................... 18
             Strength - Partnership and Collaborations ................................................................................................................................ 18
             Strength - Focused Research and Development ...................................................................................................................... 18
             Strength - Strong Intellectual Property Portfolio ........................................................................................................................ 18
          MediciNova, Inc. - Weaknesses .................................................................................................................................................... 18
             Weakness - History of Operating Losses .................................................................................................................................. 18
             Weakness - Lack of In-House Manufacturing Facilities ............................................................................................................. 19
          MediciNova, Inc. - Opportunities ................................................................................................................................................... 19
             Opportunity - Strong Product Pipeline ....................................................................................................................................... 19
             Opportunity - Emerging Markets ............................................................................................................................................... 19
             Opportunity - Changing Demographics ..................................................................................................................................... 19
          MediciNova, Inc. - Threats ............................................................................................................................................................ 19
             Threat - Highly Competitive Environment .................................................................................................................................. 19
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 20
             Threat - Tightening of FDA’s Regulatory Oversight ................................................................................................................... 20
       MediciNova, Inc. - Key Competitors ................................................................................................................................................. 21
       Section 3 – Company Financial Ratios ............................................................................................................................................. 22
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 22
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 22
       Performance Chart ........................................................................................................................................................................... 23
       Financial Performance...................................................................................................................................................................... 23
       Financial Ratios - Interim Ratios....................................................................................................................................................... 24
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 25
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 26
          MediciNova, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 ................................................................. 26


MediciNova, Inc. (MNOV) - Financial and Strategic SWOT Analysis                                                                                                Reference Code: GDPH61527FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          MediciNova, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 ................................................................. 27
       MediciNova, Inc., Recent Deals Summary ....................................................................................................................................... 28
       Section 5 – Company’s Recent Developments ................................................................................................................................ 29
          MediciNova, Inc., Recent Developments ...................................................................................................................................... 29
             Aug 09, 2012: MediciNova Reports Revenue Of $0.5m In Q2 2012 ......................................................................................... 29
             May 10, 2012: MediciNova Reports Q1 2012 Results .................
				
DOCUMENT INFO
Description: MediciNova, Inc. (MediciNova) is a bio pharmaceutical company with focus on the acquiring and developing and commercializing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need in the US. MediciNova built a portfolio of product candidates by acquiring product rights through license agreements with mid-sized Japanese pharmaceutical companies. Its clinical pipeline include six clinical stage compounds and two pre clinical stage compounds targeted against multiple sclerosis, interstitial cystitis, cancer, generalized anxiety disorder, acute exacerbations of asthma and exacerbations of chronic obstructive pulmonary disease (COPD0, asthma, preterm labor, urinary incontinence and thrombotic disorders. Currently, the company focuses on the development and commercialization of MN-221, is targeted against acuteexacerbations of asthma and COPD exacerbations, and ibudilast (MN-166/AV411). MediciNova is headquartered in San Diego, California, the US.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.